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Background: Dopamine D1 receptors (encoded by DRD1) are implicated in drug
addiction and high‐risk behaviors. Delay discounting (DD) procedures measure deci-
sional balance between choosing smaller/sooner rewards vs larger/later rewards.
Individuals with higher DD (rapid discounting) are prone to maladaptive behaviors
that provide immediate reinforcement (eg, substance use). DRD1 variants have been
linked with increased DD (in healthy volunteers) and opioid abuse. This study deter-
mined whether four dopaminergic functional variants modulated heroin DD and
impulsivity.
Methods: Substance use, DD, and genotype data (DRD1 rs686 and rs5326, DRD3
rs6280, COMT rs4680) were obtained from 106 current heroin users. Subjects com-
pleted an array of DD choices during two imagined conditions: heroin satiation and
withdrawal. Rewards were expressed as $10 heroin bag units, with maximum delayed
amount of 30 bags. Delays progressively increased from 3 to 96 hours.
Results: DRD1 rs686 (A/A, n = 25; G/A, n = 56; G/G, n = 25) was linearly related to
the difference in heroin DD (area under the curve; AUC) between the heroin satiation
and withdrawal conditions; specifically, G/G homozygotes had a significantly smaller
(satiation minus withdrawal) AUC difference score had higher drug‐use impulsivity
questionnaire scores, relative to A/A homozygotes, with G/A intermediate. DRD3
and COMT variants were not associated with these DD and impulsivity outcomes.
Conclusion: DRD1 rs686 modulated the difference in heroin DD score between
pharmacological states and was associated with drug‐use impulsivity. These data sup-
port a role of DRD1 in opioid DD and impulsive behaviors.
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Delay discounting (DD) procedures measure the decisional balance
between choosing a smaller/sooner reward versus a larger/later
reward1; selecting a smaller reward sooner (steeper discounting) is
associated with extent of impulsive behavior in that situation.2 Individ-
uals with steeper discounting are prone to maladaptive behaviors (eg,wileyonlinelibrary.com/journal/substance use).3 Relative to healthy controls, heroin users choose
more immediate reinforcers.4 Traditional discounting methods assess
DD over relatively long intervals (eg, months to years), which may
not be ecologically relevant for a person using heroin every day.1
We previously examined heroin DD as a pharmacological‐state mea-
sure among regular heroin users, employing a condensed time scale
to make the paradigm more relevant to real‐world drug use.5 The© 2019 Society for the Study of Addictionadb 1 of 8
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during an imagined opioid withdrawal than satiation condition. In the
satiation condition, individuals with lower IQ and higher drug‐use
impulsivity scores exhibited steeper heroin discounting.5
Previous studies have found that DD with nondrug goods is mod-
ulated by dopamine genetic variation and these variations have been
associated with high‐risk behaviors, including substance use.3,6-8
Although most opioid pharmacogenetic studies focus on opioid recep-
tor mutations, opioid use indirectly stimulates dopamine, thus func-
tional dopamine genetic variants could also relate to opioid‐use
behaviors.9,10 Several studies have explored the role of dopamine
D2 receptors in chronic substance use,11-13 but minimal research has
focused on more acute decision‐making in substance use and D1
receptor specifically.
The D1 receptor is a G‐protein coupled receptor primarily
expressed in the striatum, and has several functional single nucleotide
polymorphisms (SNPs).14 D1 receptors have been implicated in multi-
ple brain functions including reward and reinforcement.15-17 Although
both D1 and D2 receptors are associated with decision‐making and
reward, the varying roles and locations of these receptors result in dif-
ferent effects. For example, within the prefrontal cortex (PFC), phar-
macological studies suggest D2 receptors are involved in flexible
decision making (eg, making a new choice when the likelihood of loss
of reward is high) whereas D1 receptors are involved in maintaining a
choice (eg, making the same choice despite a high likelihood of loss of
reward).18 This complementary role for D1 and D2 receptors is also
seen in learning paradigms. Research suggests D1 receptors are
involved with learning to initiate actions whereas D2 receptors are
involved with learning to inhibit actions.14,19 D1 receptor density or
activation in certain brain regions (eg, insular cortex, PFC, and thala-
mus) also modulates impulsive decision‐making,20-22 and systemic
administration of a D1 antagonist increased preference for a smaller‐
sooner reward over a larger‐later reward, ie, impulsive choice.20,23
Some studies have found DRD1 variants to be linked with alcohol
and tobacco use disorders (reviewed by24) and with altered DD in
healthy volunteers.3 To our knowledge, only one published study has
related DRD1 polymorphisms to behavioral variation among regular
opioid users, finding an association with rate of progression to heroin
dependence in a Chinese Han sample.25 A literature review suggested
four different functional SNPs relevant to dopaminergic activity and
acute decision‐making: two DRD1 SNPs (rs686 and rs5326),15,26
DRD3 rs6280,7,27 and Catechol‐O‐methyltransferase (COMT)
rs4680.27,28 DRD3 rs6280 was included because it has been previ-
ously associated with several types of substance use/dependence
(see review by Le Foll et al24) and this specific variant is associated
with aberrant decision making29 and with modulating response to
reward.30 We included COMT in our analyses because it affects dopa-
mine concentrations in the PFC, an area strongly implicated in reward‐
related decision‐making.31
The present candidate gene study is aimed to determine whether
dopamine‐system functional variants modulated heroin DD and
drug‐use impulsivity. We hypothesized that dopamine genetic varia-
tion would be related to DD. On the basis of findings of our previouswork on DD in heroin users, we also hypothesized that dopamine
genetic variation would be associated with IQ and drug‐use impulsiv-
ity scores.52 | MATERIALS AND METHODS
2.1 | Participants
This study used screening data from four laboratory studies approved
by the Institutional Review Boards at Wayne State University and the
University of Michigan, registered under clinical trials NCT00218309,
NCT00218361, NCT00608504, and NCT00684840. Participants
were recruited via print media advertisements and word‐of‐mouth
referral from the Detroit, Michigan Metropolitan Area.
Nontreatment‐seeking individuals between 18 and 55 years of age
who used heroin regularly (at least weekly) and denied any major med-
ical or psychiatric disorders during an initial phone screening were
invited for an in‐person visit. Participants were eligible to complete
the in‐person battery if they tested positive for opioid use (more than
300 ng/mL), negative for alcohol (less than 0.002%; Alco Sensor III
Breathalyzer), and were cognitively intact (total IQ score greater than
or equal to 80 on the Shipley Institute of Living Scale32).2.2 | Genotyping
Blood samples were collected and participant DNA was extracted
using the Qiagen kit (formerly Gentra Puregene). The Golden Gate
drug addiction Illumina panel33 was used to genotype the blood sam-
ples. For this analysis, we focused on dopamine‐system genetic vari-
ants: DRD1 rs686 [3′UTR; G/A] and rs5326 [5′UTR; G/A], DRD3
rs6280 [missense; C/T, Ser9Gly], and COMT rs4680 [missense; G/A,
Val158Met].2.3 | Phenotyping
Substance use characteristics were measured using the Drug History
and Use Questionnaire (available on request). As previously
described,5 delay discounting measures were obtained during two
within‐subject, experimental conditions: imagined heroin satiation
and withdrawal. The order of these two imagined conditions was ran-
domized for each participant. Rewards were expressed as $10 heroin
bag units (21 decreasing values from 30 to 0.3 bags), with seven
increasing delays (3, 6, 12, 24, 48, 72, and 96 h) to a delayed amount
of 30 bags. This task was chosen as it allowed us to focus on the inno-
vative question as to whether a simulated pharmacological‐state con-
dition alters heroin DD. As this is a novel task there are no data on its
test–retest reliability; however, studies show that traditional monetary
DD measures and some variations on the task (eg, sexual discounting)
are reliable in retesting conditions.34-36 Drug‐use impulsivity was mea-
sured with the 30‐item Impulsive Relapse Questionnaire (IRQ) which,
unlike indices of trait impulsivity, specifically measures impulsivity as
it relates to using drugs (eg, impulsive choice to purchase more
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Control Deficit, Denial, and Capacity for Delay. Ancestral race was
measured by self‐report. We previously used ancestry informative
markers to confirm self‐reported racial identity in this sample.382.4 | Data analyses
Area under the curve (AUC) was used to measure DD, as it was nor-
mally distributed and well suited for ANOVA and correlations.39 Initial
analyses used repeated measures mixed‐model analysis of covariance
(ANCOVA) with genotype as the between‐subjects factor (separate
analysis for each genotype), pharmacological‐state condition (eg, her-
oin satiation vs withdrawal) as within‐subject factor and race and IQ
as covariates. For any significant effects, we also conducted stepwise
linear regression analyses, controlling for IQ, which explained variance
in our earlier study5 and race because it is an important factor in
genetic studies.40,41 We chose to conduct ANCOVA as the primary
analysis with secondary linear regression because ANCOVA provides
information about the initial significant interactions, whereas the sub-
sequent regression allows us to more thoroughly consider the poten-
tial contributions of other covariates. Following initial analyses, a DD
difference score was calculated from the difference between the
AUC in each imagined condition. This difference score was used as a
simple way to display the statistical interactions between genotype
and condition and represents pharmacological sensitivity to the shift
from satiation to withdrawal.
Within each genotype, we measured the allelic distribution to
check for adequate group sizes and covaried for race and IQ because
of our prior findings.5 All descriptive data are presented as mean ± one
standard deviation. All analyses were conducted with SPSS v.25 andTABLE 1 DRD1 rs686 genotype distributions and allele frequencies
DRD1 rs686 (N) A/A G/A G/G
Black (59) 12 (20.3%) 28 (47.5%) 19 (32.2%)
White (47) 13 (27.7%) 28 (59.6%) 6 (12.8%)
Overall (106) 25 (23.6%) 56 (52.8%) 25 (23.6%)
TABLE 2 DRD3 rs6280 genotype distributions and allele frequencies
DRD3 rs6280 (N) A/A A/G G/G
Black (59) 5 (8.5%) 24 (40.7%) 30 (50.8%)
White (47) 21 (44.7%) 23 (48.9%) 3 (6.4%)
Overall (106) 26 (24.5%) 47 (44.3%) 33 (31.1%)
TABLE 3 COMT rs4680 genotype distributions and allele frequencies
COMT rs4680 (N) A/A A/G G/G
Black (58) 4 (6.9%) 24 (41.4%) 30 (51.7%
White (47) 8 (17.0%) 26 (55.3%) 13 (27.7%
Overall (105) 12 (11.4%) 50 (47.6%) 43 (41.0%used the criterion of P < .05 to reject the null hypothesis. We include
DD effect size estimates using partial eta‐squared (η2).3 | RESULTS
3.1 | Participant characteristics
We obtained complete data from 106 heroin‐using participants. The
average participant was a 42.7 ± 10.0‐year‐old African American
(55.7%) male (72.6%) with 12.2 ± 1.4 years of education and a Shipley
estimated IQ score of 104.4 ± 10.8. On average, participants had been
using heroin for 20.4 ± 12.6 years and initiated heroin use at
22.4 ± 6.5 years old.
We obtained results for DRD1 rs5326 but did not analyse this var-
iant further as minor allele frequency was too low. Using an online cal-
culator, http://www.oege.org/software/cubex/,42 we found DRD1
rs686 was in high linkage disequilibrium with rs5326 but not substitut-
able (r2 = 0.2114; D′ = 1.00). As expected (ie, because DRD1, DRD3,
and COMT are located on different chromosomes), rs686 was not in
LD with DRD3 rs6280 (r2 = 0.0175; D′ = 0.141) or COMT rs4680
(r2 = 0.0174; D′ = 0.179). Table 1 shows genotype and allelic frequen-
cies for DRD1 rs686 for African Americans (n = 59), Caucasians
(n = 47), and overall sample (N = 106). Using an online calculator,
http://www.oege.org/software/hardy‐weinberg.html,43 genotype fre-
quencies for rs686 did not deviate significantly from the Hardy‐
Weinberg equilibrium (HWE) in the overall samples or in the African
American or Caucasian subsamples (ps > 0.05). Allelic frequencies
did not differ significantly by race (χ2 = 5.51; P = .064), therefore,
we conducted analyses in the combined sample. Tables 2 and 3 show
genotype and allelic distributions for the other two SNPs, which did
not deviate from HWE.A allele G allele HWE χ2 P
52 (44.1%) 66 (55.9%) 0.08 .775
54 (57.4%) 40 (42.6%) 2.24 .134
106 (50%) 106 (50%) 0.34 .560
A allele G allele HWE χ2 P
34 (28.8%) 84 (71.2%) 0.004 .949
65 (69.1%) 29 (30.9%) 1.02 .314
99 (46.7%) 113 (53.3%) 1.27 .260
A allele G allele HWE χ2 P
) 32 (27.6%) 84 (72.4%) 0.07 .786
) 42 (44.7%) 52 (55.3%) 0.67 .414
) 74 (35.2%) 136 (64.8%) 0.20 .657
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Heroin DD overall (ie, averaged across pharmacological‐state condi-
tion) did not significantly differ for any of the genotypes examined.
There was no main effect of genotype on DD score in either the sati-
ation condition ( F 2,101 = 0.44, P = .643, η
2 = 0.009) or the withdrawal
condition ( F 2,101 = 2.05, P = .134, η
2 = 0.039). This indicates that the
DD score was not significantly different across genotypes in either
condition. We did find a significant interaction of DRD1 rs686 (G/G,
n = 25; G/A, n = 56; A/A, n = 25) and condition, F 2,101 = 3.66,
P = .029, η2 = 0.068 (Figure 1) after controlling for race and IQ, indicat-
ing there is a significant relationship between genotype and the
change in response to imagined conditions in this DD paradigm. After
discovering an interaction effect and no simple main effects, we com-
puted the (satiation minus withdrawal) AUC difference score to reflect
change in DD between the two conditions (Figure 2). This difference
score is used as a marker of pharmacological sensitivity as it shows
the change in DD response between the two conditions. We observed
an allelic dose‐effect: the G/G group had a significantly greater change
in DD between conditions than the A/A group, and the heterozygous
(G/A) group was intermediate and did not significantly differ from
either homozygote group. DRD1 rs686 remained significantly related
to the change in DD, F 2,101 = 3.66, P = .029, when controlling for
IQ, F 1,101 = 15.89, P < .001, η
2 = 0.136, and race, F 1,101 = 5.34,
P = .023, η2 = 0.050. To ensure the differences we found were related
to differences in discounting between the two conditions rather thanFIGURE 1 Mean (1 SEM) heroin delay‐discounting area‐under‐the‐curv
pharmacological‐state conditions, by DRD1 rs686 genotype and race
FIGURE 2 Mean (1 SEM) change in heroin delay‐discounting area‐under‐
DRD1 rs686 genotype and racealternative confounding factors, we also examined mean indifference
points per group per discounting state (Figure 3). This analysis showed
that from the 12‐hour time delay onward, there is a stable difference
in the change score illustrating that the significant interaction effect is
because of the alteration in discount rate (ie, grows with delay to her-
oin receipt) rather than other confounding factors.
We conducted a stepwise linear regression analysis, again control-
ling for race and IQ, to explore the predictive effect of DRD1 rs686
genotype on the heroin DD difference score. The final model (step
3) included IQ (β = .351; t = 3.91, P < .001, Δr2 = 0.113), DRD1
rs686 (β = −.224; t = −2.46, P = .016, Δr2 = 0.035), and race
(β = −.200; t = −2.18, P = .032, Δr2 = 0.038) and was significant over-
all, F 2,105 = 7.74, P < .001, explaining 16.1% of total adjusted variance
in the DD difference score. This finding shows that IQ, genotype, and
race all independently play significant roles in the difference score
between the two imagined conditions in heroin DD.3.3 | Other phenotypes
We observed no significant genotype differences for any demographic
characteristics (Table 4) but again controlled for race. DRD1 rs686 A/A
homozygotes (vs G/G, with G/A intermediate) had higher IRQ speed
scores. DRD3 and COMT variants were unrelated to impulsivity out-
comes (ie, IRQ scores).e (AUC) scores during participant‐imagined satiation and withdrawal
the‐curve (AUC) scores between pharmacological‐state conditions, by
FIGURE 3 Mean (1 SEM) heroin delay‐discounting indifference points for satiation and withdrawal conditions as a function of DRD1 rs686
genotype (upper row) and time course of (satiation–withdrawal) difference score for each genotype group (lower panel)
TABLE 4 Demographic and substance use characteristic variation for DRD1 rs686 genotypes in the overall sample
A/A (n = 25) G/A (n = 56) G/G (n = 25) χ2/F P
Sex (male) 76.0% (19) 69.6% (39) 76.0% (19) 0.54 .764
Age (years) 41.4 ± 9.3 41.8 ± 10.5 46.1 ± 9.0 1.89 .156
Estimated IQ 105.6 ± 11.7 103.7 ± 10.0 104.6 ± 11.7 0.28 .758
Current injection drug use 68.0% (17) 58.9% (33) 44.0% (11) 3.04 .219
IRQ speed¶ 9.6 ± 3.5b 11.4 ± 3.6ab 12.3 ± 4.1a 3.47 .035
Total heroin‐use consequences 9.7 ± 4.4 8.7 ± 5.0 7.7 ± 4.9 1.10 .337
Number of heroin quit attempts 9.7 ± 19.6 12.0 ± 22.5 10.7 ± 20.l 0.14 .868
¶Shared superscripts indicate non‐significant differences between group means in post hoc tests.
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The present study examined how dopaminergic genetic variation
impacted ecologically‐relevant (brief time‐scale) heroin DD under dif-
ferent simulated pharmacological conditions and drug‐use impulsivity
among out‐of‐treatment heroin users. We studied functional polymor-
phisms implicated in opioid use disorder that are related to dopami-
nergic activity and acute decision‐making: DRD1 rs686,15,24,26 DRD3
rs6280,7,27 and COMT rs4680.27,28 We hypothesized that dopaminer-
gic genetic variation would be associated with heroin DD, IQ, and
drug‐use impulsivity.5 Although none of these dopamine genetic‐
variants was associated with overall rates of heroin DD under satia-
tion and withdrawal conditions, DRD1 rs686 was uniquely associated
with the change in heroin discount rate between satiation and with-
drawal conditions.Among these heroin users, DRD1 rs686 genotype (after control-
ling for IQ and race) explained 4.2% of variance in the change in
discounting between pharmacological‐state conditions. There was
an allelic dose‐effect: G/G homozygotes discounted heroin more
than A/A homozygotes or A/G heterozygotes in the satiation condi-
tion and comparatively less in the withdrawal condition, resulting in
a significantly smaller change in AUC between the two conditions
(Figure 2). We theorize that the DD difference score reflects sensi-
tivity to the dynamic shift between opioid satiation vs withdrawal
(use vs abstinence) states that these habitual heroin users regularly
encounter. Thus, A/A homozygotes exhibited greater sensitivity to
changes in simulated pharmacological state (ie, larger shift in heroin
DD from satiation to withdrawal) than G/G homozygotes. This geno-
type group difference in heroin discounting was not evident at 3‐
and 6‐hour delays, but was larger and consistent from the 12‐hr to
6 of 8 MOSES ET AL.96‐hr time period measured (Figure 3). We did not find any main
effect between DRD1 rs686 genotype and DD. We developed the
difference score in response to the significant interaction effect
between genotype and condition. The finding of this interaction
effect in the absence of a main effect suggests this genotype plays
a larger role in sensitivity to change in opioid agonist stimulation
level (as measured by the DD change score) than discounting itself.
Taken together, our findings suggest that DRD1 genotype modulates
pharmacological state‐dependent (satiation minus withdrawal) change
in heroin discounting, an effect that grows with delay to receipt
of heroin.
Although demographic and substance‐use characteristics (Table 4)
did not significantly differ by DRD1 rs686 genotype, there was an alle-
lic dose‐effect for IRQ Speed subscale scores. This aligns with our pre-
vious findings that higher IRQ speed scores were associated with
greater heroin DD.5 We did not find an association between IQ and
DRD1 genotype. We postulated this relationship based on our obser-
vations that lower IQ was associated with more impulsive drug
choices5; the lack of association here suggests the IQ/impulsivity rela-
tionship may be separate from the one we see between dopaminergic
genetic variation and drug‐use impulsivity.
The biological impact of DRD1 rs686 plausibly relates to these
behavioral findings. Previous studies found the A‐allele is associated
with increased DRD1 gene expression and D1 receptor density19,44
relative to G‐allele carriers, which may partly explain differences in
pharmacological‐state heroin discounting in this study. A‐allele carriers
have higher D1 receptor density and thus might be more sensitive to
dynamic state‐dependent changes in dopamine that occur during drug
satiation and withdrawal (which can happen on a daily basis for heroin
users). Previous research has demonstrated results that support this
theory of increased sensitivity. One study found that individuals with
A‐alleles were most likely to continue to experience opioid‐induced
euphoria even after chronic use.45 This contrasts with G‐allele carriers
who may have decreased D1 receptor expression, possibly resulting in
their overall higher rates of discounting and decreased difference
score. This theory is supported by the fact that systemic administra-
tion of a D1 antagonist has been shown to increase discounting.20,23
This theory is also enhanced by our finding that individuals with G‐
alleles had a higher IRQ speed score indicating increased drug use
impulsivity. Additionally, G‐allele carriers have been shown to exhibit
more depressive symptoms than A‐allele carriers.46 Depressive symp-
toms are associated with impairments in emotion regulation and cog-
nitive control,47 which may decrease sensitivity to pharmacologic‐
state changes among G‐allele carriers.
The present study has several limitations. First, substance‐use
variables were self‐reported, which may introduce recall bias. Sec-
ond, the DD paradigm required participants to imagine heroin‐
satiated and withdrawal conditions without specific guidance; yet,
there is no direct means to confirm they imagined the correct sce-
nario. Despite this concern, the present findings align with prior work
using this paradigm in opioid‐dependent individuals,48 which sug-
gests consistency in the imagined conditions. Third, we have a rela-
tively small sample size, which may have resulted in a lack ofpower. Fourth, we used nonstandard experimental conditions for this
study. Both the relatively short delay times and the within‐subjects
comparison of the two conditions and the absence of a monetary
DD task, are not standard relative to the existing literature, which
may influence the relevance of our findings. Fifth, although we did
collect information about major medical and psychiatric conditions,
we excluded these covariates in the analyses because of concerns
of confounding and multiple comparisons. Unfortunately, this also
means that our findings are less generalizable because co‐occurring
conditions are common among this population. Sixth, we used self‐
reported race/ethnicity rather than ancestral informative markers
and although these two measures are highly correlated,49 genetic
markers are more specific.41 However, our prior use of ancestral
markers to confirm self‐reported race in this sample,38 and our
finding that race was not significantly associated with DRD1 rs686
allelic variation, reduces the impact of this potential limitation. Sev-
enth, this study is a candidate gene study, which comes with its
own limitations.50 These analyses were based on a priori assumptions
about the genes and pathways in question and it is possible that our
underlying assumptions are incorrect. Furthermore, although these
findings align with our hypotheses of the mechanisms underlying
these differences, this study design does not allow us to know
whether the candidate gene in question is the causal mechanism
for this observation.
Our findings indicate an important relationship between the DRD1
gene and acute drug‐use decision‐making and impulsive behaviors.
We found DRD1 modulated the shift in heroin, discounting between
the two pharmacological‐state conditions and was associated with
drug‐use impulsivity. These data support a role of DRD1 in opioid
DD and impulsive drug‐use behaviors. DRD1 variants could be useful
markers for understanding impulsive behaviors in opioid‐dependent
individuals. The use of behavioral measures has proved integral in
our understanding of substance use, and pharmacogenetic analyses
of these phenotypes could improve our mechanistic understanding
and approaches to addiction treatment.ACKNOWLEDGEMENTS
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